^
Association details:
| Biomarker: | EGFR amplification |
|---|---|
| Cancer: | Squamous Cell Carcinoma of Head and Neck |
| Drug Class: | Immunotherapy |
| Direction: | Resistant |
Evidence:
Source:
Title:
Patterns of Response to Immune Checkpoint Inhibitors in Association with Genomic and Clinical Features in Patients with Head and Neck Squamous Cell Carcinoma (HNSCC)
Published date:
01/14/2021
Excerpt:
HPD was observed in 15.4 % of patients with R/M HNSCC treated with IO and was associated with worse PFS and OS. EGFR amplification was identified in patients with HPD.
DOI:
10.3390/cancers13020286
